Correction to: Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis

Na Li¹ · Zhong-Ping Gou¹ · Shuang-Qing Du¹ · Xiao-Hong Zhu¹ · Hui Lin² · Xiu-Fang Liang¹ · Yong-Sheng Wang¹ · Ping Feng¹

Published online: 27 January 2022

© International League of Associations for Rheumatology (ILAR) 2022

Correction to: Clinical Rheumatology

<https://doi.org/10.1007/s10067-021-06003-z>

In the original published version of the above article contained the following errors and should have been corrected. [Bold emphasis shows the error area]

1. The Affiliation “National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Institute of Clinical **Trials**, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China” should have been “National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Institute of Clinical **Trial Center**, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China”
2. Under the “Study characteristics” of “Results” section, the total number of article obtained in the text “After

searching Pubmed, Medline, Embase, and Cochrane Controlled Trials Register databases a total of **806** articles was obtained.” should have been **906** instead of **806**. In the text, “After excluding duplicates, the title, abstract or full text of **488** articles were read to assess their eligibility according to inclusion and exclusion criteria.” The correct number of articles read should have been **570** instead of **488** and the text “After excluding duplicates, the title, abstract **or** full text of **488** articles were read...” should be read as “After excluding duplicates, the title, abstract **and** full text of **488** articles were read...”

3. The Tables 2, 3, 4 and Figure 4 were not presented correctly. The corrected Tables and Figure are shown here.

The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1007/s10067-021-06003-z>

✉ Ping Feng
fengping@wchscu.cn; pfyq@yahoo.com

¹ National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Institute of Clinical Trial Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China

² Department of Rheumatology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China

Table 2 Characteristics of studies included in the systematic review and network meta-analysis of the effect of JAK inhibitors on lipoprotein levels in rheumatoid arthritis (RA) patients

Study	Study type	Study drug (no. of patients)	female patients(n%)	Age (years)	RA duration (years)	Baseline DAS28	Follow-up (weeks)
Fleischmann et al. 2012	Phase IIb	Tofacitinib (49)	87.8	54 ± 13.5	13.7 ± 8.4	5.6	24
		Placebo (59)	88.1	53 ± 13.7	16.6 ± 10.4	5.6	24
Kremer et al. 2012	Phase IIb	Tofacitinib (71)	80.3	52 ± 12.8	16.1 ± 9.6	5.1	24
		Placebo (69)	81.2	53 ± 13.4	14.5 ± 8.1	5.3	24
Kremer et al. 2009	Phase IIa	Tofacitinib (61)	86.9	47.9 ± 10.8	10.2	6.2	6
		Placebo (65)	84.6	51.3 ± 12.1	8.7	6.0	6
Fleischmann et al. 2017	Phase III	Baricitinib (215)	73	49 ± 14	1.3 ± 2.7	5.9	52
		Placebo (210)	70	51 ± 13	1.3 ± 4	5.9	52
Taylor et al. 2017	Phase III	Baricitinib (487)	77	54 ± 2	10 ± 9	5.8	24
		Placebo (488)	78	53 ± 2	10 ± 9	5.7	24
Dougados et al. 2016	Phase III	Baricitinib (227)	82	52 ± 12	8 ± 8	5.6	24
		Placebo (228)	83	51 ± 13	7 ± 8	5.5	24
Genovese et al. 2016	Phase III	Baricitinib (177)	84	56 ± 11	14 ± 9	5.9	24
		Placebo (176)	82	56 ± 11	14 ± 10	5.9	24
Tanaka et al. 2016	Phase IIb	Baricitinib (24)	79	57.5 ± 10.4	5.9 ± 4	4.96	12
		Placebo (49)	80	51.1 ± 12	5.1 ± 4	4.72	12
Keystone et al. 2014	Phase IIb	Baricitinib (52)	71	53 ± 10	5.3 ± 4.5	5.3	12
		Placebo (98)	87	49 ± 12	5.4 ± 4.3	5.5	12
Takeuchi et al. 2019	Phase III	Peficitinib (174)	71.8	56.2 ± 11.6	4.4 ± 3.1	5.4	12
		Placebo (170)	71.2	55.3 ± 12.1	4.3 ± 2.9	5.4	12
Tanaka et al. 2019	Phase III	Peficitinib (102)	76.5	55 ± 12.8	10.4 ± 8.2	5.4	12
		Placebo (101)	72.3	56.3 ± 11.7	7 ± 6.6	5.4	12
Genovese et al. 2017	Phase IIb	Peficitinib (64)	78.1	54.4 ± 12.5	10.5 ± 8.2	5.9	12
		Placebo (51)	82.4	52.7 ± 12.2	9.8 ± 7.7	5.9	12
Kivitz et al. 2016	Phase IIb	Peficitinib (78)	82.1	54.2 ± 12.5	7.3 ± 6.3	5.6	12
		Placebo (72)	87.5	52.6 ± 12.2	7.2 ± 7.7	5.4	12

Table 2 (continued)

Study	Study type	Study drug (no. of patients)	female patients(n%)	Age (years)	RA duration (years)	Baseline DAS28	Follow-up (weeks)
Takeuchi et al.2015	Phase IIb	Peficitinib (58)	88	51.6 ± 12.1	7 ± 5.2	5.4	12
		Placebo (56)	77	54.2 ± 12.1	6.9 ± 5.4	5.1	12
Combe et al. 2021	phase III	Filgotinib (480)	83.1	53±12.6	8.5±8.2	5.7	24
		Placebo (475)	82.3	53±12.8	7.3±7.2	5.7	24
Kavanaugh et al. 2016	Phase IIb	Filgotinib (70)	75.7	53 ± 1.4	9 ± 0.8	6.2	12
		Placebo (72)	77.8	52.0 ±1.4	10.0 ±0.8	6.2	12
Rubbert-Roth et al. 2020	Phase III	Upadacitinib (303)	82	55.3 ± 11.4	12.4 ± 9.5	5.7	24
		Abatacept (309)	82	55.8 ± 11.9	11.8 ± 8.3	5.9	24
Fleischmann et al. 2019	Phase III	Upadacitinib (651)	80	54 ± 12	8 ± 8	5.8	14
		Placebo (651)	79	54 ± 12	8 ± 8	5.8	14

Dosage of JAK inhibitors: tofacitinib, 5 mg twice daily; baricitinib, 4 mg once daily; upadacitinib, 15 mg once daily; peficitinib, 150 mg once daily; filgotinib, 100 mg once daily. DMARDS means disease modifying antirheumatic drug; DAS28, disease activity score in 28 joints; NA, no data available

Table 3 League table: network meta-analysis results comparing the effects of JAK inhibitors on high-density lipoprotein levels (mg/dl)

	Baricitinib							
Filgotinib	1.67 (-4.94, 8.22)	Filgotinib						
Peficitinib	-2.86 (-7.86, 1.97)	-4.53 (-11.35, 2.15)	Peficitinib					
Placebo	7.75 (4.41, 11.10)	6.09 (0.40, 11.77)	10.61 (7.08, 14.30)	Placebo				
Tofacitinib	1.24 (-5.75, 8.29)	-0.40 (-8.74, 7.95)	4.11 (-2.95, 11.31)	-6.51 (-12.68, -0.34)	Tofacitinib			
Upadacitinib	0.50 (-7.87, 8.82)	-1.17 (-10.71, 8.38)	3.35 (-5.04, 11.88)	-7.26 (-14.91, 0.37)	-0.75 (-10.64, 9.02)	Upadacitinib		

The value in the box indicates the mean difference (95% CI) between the drug listed horizontally and the drug listed vertically

Table 4 League table: network meta-analysis results comparing the effects of JAK inhibitors on low-density lipoprotein levels (mg/dl)

	Baricitinib						
Filgotinib	5.052 (-4.67, 14.33)	Filgotinib					
Peficitinib	7.03 (-0.17, 13.79)	1.96 (-7.79, 11.67)	Peficitinib				
Placebo	13.53 (8.72, 18.19)	8.47 (0.37, 16.92)	6.50 (1.52, 11.79)	Placebo			
Tofacitinib	-0.07 (-11.88, 11.51)	-5.12 (-18.60, 8.47)	-7.06 (-18.95, 4.78)	-13.59 (-24.38, -3.02)	Tofacitinib		
Upadacitinib	-8.24 (-19.88, 3.28)	-13.33 (-26.49, 0.33)	-15.30 (-26.81, -3.37)	-21.78 (-32.28, -11.20)	-8.21 (-23.03, 6.91)	Upadacitinib	

The value in the box indicates the mean difference (95% CI) between the drug listed horizontally and the drug listed vertically

Fig. 4 Pooled estimates of relative risk of major cardiovascular events in rheumatoid arthritis patients, stratified by JAK inhibitor treatment